Action Dicerna Pharmaceuticals - DRNA

Dicerna Pharmaceuticals Inc (DRNA) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

38,22

( - )

Prix Achat

42,07

Prix Vente

38,22

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

38,22

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a...

Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has...

Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of...

Direxion Launches mRNA ETF (MSGR)

Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK, Dec. 9, 2021 NEW YORK, Dec. 9, 2021...

Dicerna Shares Soar on Takeover by Novo Nordisk

By Colin Kellaher Shares of Dicerna Pharmaceuticals Inc. rose nearly 80% on Thursday after the biopharmaceutical company agreed to be acquired by...

Novo Nordisk to Buy Dicerna for $38.25 a Share

By Mary de Wet Dicerna Pharmaceuticals Inc. said Thursday that Novo Nordisk AS would buy the biopharmaceutical company for $38.25 per share in...

Novo Nordisk to Acquire Dicerna

– Acquisition to Accelerate and Expand Novo Nordisk Development of RNAi Therapeutics Using Dicerna’s Proprietary GalXC™ Technology Platform...

Dicerna Pharma: Two Targets in Lilly Collaboration Meet Proof of Principle

By Chris Wack Dicerna Pharmaceuticals Inc. said that Eli Lilly and Co. has declared proof of principle for the first two targets in the...

Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly

– Milestone Triggers Two Single-Digit Multimillion-Dollar Payments to Dicerna – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading...

Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

– Belcesiran Was Shown to Be Safe and Well Tolerated in Phase 1 Trial and Demonstrated Robust, Dose-Dependent Reductions in Serum Alpha-1...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

DRNA - Frequently Asked Questions (FAQ)

What is the current Dicerna Pharmaceuticals Inc share price?

The current share price of Dicerna Pharmaceuticals Inc is US$ 38,22

What is the 1 year trading range for Dicerna Pharmaceuticals Inc share price?

Dicerna Pharmaceuticals Inc has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Dicerna Pharmaceuticals Inc (DRNA)

Dicerna Pharmaceuticals Inc (DRNA) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

DRNA Dernières nouvelles

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition